[1]
|
牟鹏, 厉红元. 乳腺癌新辅助化疗的研究进展[J]. 中国普外基础与临床杂志, 2011, 18(9): 1011-1016.
|
[2]
|
Goetz, M.P., Gradishar, W.J., Anderson, B.O., Abraham, J., Aft, R., Allison, K.H., et al. (2019) NCCN Guidelines Insights: Breast Cancer, Version 3.2018. Journal of the National Comprehensive Cancer Network, 17, 118-126.
https://doi.org/10.6004/jnccn.2019.0102
|
[3]
|
高宇, 郭仁德. 乳腺癌根治术后上肢淋巴结水肿发病机制及治疗研究进展[J]. 四川解剖学杂志, 2020, 28(2): 196-197.
|
[4]
|
Fleissig, A., Fallowfield, L.J., Langridge, C.I., Johnson, L., Newcombe, R.G., Dixon, J.M., et al. (2006) Post-Operative Arm Morbidity and Quality of Life. Results of the ALMANAC Randomised Trial Comparing Sentinel Node Biopsy with Standard Axillary Treatment in the Management of Patients with Early Breast Cancer. Breast Cancer Research and Treatment, 95, 279-293. https://doi.org/10.1007/s10549-005-9025-7
|
[5]
|
Kuehn, T., Bauerfeind, I., Fehm, T., Fleige, B., Hausschild, M., Helms, G., et al. (2013) Sentinel-Lymph-Node Biopsy in Patients with Breast Cancer before and after Neoadjuvant Chemotherapy (SENTINA): A Prospective, Multicentre Cohort Study. The Lancet Oncology, 14, 609-618. https://doi.org/10.1016/S1470-2045(13)70166-9
|
[6]
|
Boughey, J.C., Suman, V.J., Mittendorf, E.A., Ahrendt, G.M., Wilke, L.G., Taback, B., et al. (2013) Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial. JAMA, 310, 1455-1461. https://doi.org/10.1001/jama.2013.278932
|
[7]
|
Krag, D.N., Anderson, S.J., Julian, T.B., Brown, A.M., Harlow, S.P., Costantino, J.P., et al. (2010) Sentinel-Lymph-Node Resection Compared with Conventional Axillary-Lymph-Node Dissection in Clinically Node-Negative Patients with Breast Cancer: Overall Survival Findings from the NSABP B-32 Randomised Phase 3 Trial. The Lancet Oncology, 11, 927-933. https://doi.org/10.1016/S1470-2045(10)70207-2
|
[8]
|
Mansel, R.E., Fallowfield, L., Kissin, M., Goyal, A., New-combe, R.G., Dixon, J.M., et al. (2006) Randomized Multicenter Trial of Sentinel Node Biopsy versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial. JNCI: Journal of the National Cancer Institute, 98, 599-609. https://doi.org/10.1093/jnci/djj158
|
[9]
|
Kuerer, H.M., Sahin, A.A., Hunt, K.K., Newman, L.A., Breslin, T.M., Ames, F.C., et al. (1999) Incidence and Impact of Documented Eradication of Breast Cancer Axillary Lymph Node Metastases before Surgery in Patients Treated with Neoadjuvant Chemotherapy. Annals of Surgery, 230, 72-78. https://doi.org/10.1097/00000658-199907000-00011
|
[10]
|
Kang, Y.-J., Han, W., Park, S., You, J.Y., Yi, H.W., Park, S., et al. (2017) Outcome Following Sentinel Lymph Node Biopsy-Guided Decisions in Breast Cancer Patients with Conversion from Positive to Negative Axillary Lymph Nodes after Neoadjuvant Chemotherapy. Breast Cancer Re-search and Treatment, 166, 473-480.
https://doi.org/10.1007/s10549-017-4423-1
|
[11]
|
Yu, Y., He, Z., Ouyang, J., Tan, Y., Chen, Y., Gu, Y., et al. (2021) Magnetic Resonance Imaging Radiomics Predicts Preoperative Axillary Lymph Node Metastasis to Support Sur-gical Decisions and Is Associated with Tumor Microenvironment in Invasive Breast Cancer: A Machine Learning, Mul-ticenter Study. EBioMedicine, 69, Article ID: 103460.
https://doi.org/10.1016/j.ebiom.2021.103460
|
[12]
|
Al-Hattali, S., Vinnicombe, S.J., Gowdh, N.M., Evans, A., Armstrong, S., Adamson, D., et al. (2019) Breast MRI and Tumour Biology Predict Axillary Lymph Node Response to Neoadjuvant Chemotherapy for Breast Cancer. Cancer Imaging, 19, Article No. 91. https://doi.org/10.1186/s40644-019-0279-4
|
[13]
|
Boughey, J.C., McCall, L.M., Ballman, K.V., Mittendorf, E.A., Ahrendt, G.M., Wilke, L.G., et al. (2014) Tumor Biology Correlates with Rates of Breast-Conserving Surgery and Path-ologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer: Findings from the ACOSOG Z1071 (Al-liance) Prospective Multicenter Clinical Trial. Annals of Surgery, 260, 608-616. https://doi.org/10.1097/SLA.0000000000000924
|
[14]
|
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.M., Liu, M.C., et al. (2012) Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women with Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (NeoSphere): A Randomised Multicentre, Open-Label, Phase 2 Trial. The Lancet Oncology, 13, 25-32.
https://doi.org/10.1016/S1470-2045(11)70336-9
|
[15]
|
Mamtani, A., Barrio, A.V., King, T.A., Van Zee, K.J., Plitas, G., Pilewskie, M., et al. (2016) How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Annals of Surgical Oncology, 23, 3467-3474. https://doi.org/10.1245/s10434-016-5246-8
|
[16]
|
Colleoni, M., Bagnardi, V., Rotmensz, N., Gelber, R.D., Viale, G., Pruneri, G., et al. (2009) Increasing Steroid Hormone Receptors Expression Defines Breast Cancer Subtypes Non Responsive to Preoperative Chemotherapy. Breast Cancer Research and Treatment, 116, 359-369. https://doi.org/10.1007/s10549-008-0223-y
|
[17]
|
González-Santiago, S., Saura, C., Ciruelos, E., Alonso, J.L., de la Morena, P., Santisteban Eslava, M., et al. (2020) Real-World Effectiveness of Dual HER2 Blockade with Pertuzumab and Trastuzumab for Neoadjuvant Treatment of HER2-Positive Early Breast Cancer (The NEOPETRA Study). Breast Cancer Research and Treatment, 184, 469-479.
https://doi.org/10.1007/s10549-020-05866-1
|
[18]
|
Singh, J.C., Mamtani, A., Barrio, A., Morrow, M., Sugarman, S., Jones, L.W., et al. (2017) Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Fol-lowed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. The Oncologist, 22, 139-143.
https://doi.org/10.1634/theoncologist.2016-0268
|
[19]
|
van Zeeland, M., Westhoff, P., Wauters, C., Bult, P., Werner, A., Laurens, N., et al. (2020) Omission of Axillary Lymph Node Dissection after Neoadjuvant Chemotherapy for Clini-cally Node-Positive Breast Cancer: How Can We Select Patients? The Breast Journal, 26, 1869-1870. https://doi.org/10.1111/tbj.13930
|
[20]
|
Eun, N.L., Son, E.J., Gweon, H.M., Kim, J.-A. and Youk, J.H. (2020) Pre-diction of Axillary Response by Monitoring with Ultrasound and MRI during and after Neoadjuvant Chemotherapy in Breast Cancer Patients. European Radiology, 30, 1460-1469. https://doi.org/10.1007/s00330-019-06539-4
|
[21]
|
Shirzadi, A., Mahmoodzadeh, H. and Qorbani, M. (2019) As-sessment of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy for Breast Cancer in Two Subgroups: Ini-tially Node Negative and Node Positive Converted to Node Negative—A Systemic Review and Meta-Analysis. Journal of Research in Medical Sciences, 24, Article No. 18.
https://doi.org/10.4103/jrms.JRMS_127_18
|
[22]
|
Morency, D., Dumitra, S., Parvez, E., Martel, K., Basik, M., Robidoux, A., et al. (2019) Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study. Annals of Surgical Oncology, 26, 4337-4345. https://doi.org/10.1245/s10434-019-07809-7
|